Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life.
J Clin Endocrinol Metab
; 109(10): 2541-2552, 2024 Sep 16.
Article
em En
| MEDLINE
| ID: mdl-38501238
ABSTRACT
CONTEXT Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete. OBJECTIVE:
To identify pre- and posttreatment survival predictors in a real-life cohort of RR-DTC treated with lenvatinib.DESIGN:
Multicenter, retrospective, cohort study.SETTING:
3 Italian thyroid cancer referral centers.PARTICIPANTS:
55 RR-DTC treated with lenvatinib. MAIN OUTCOMEMEASURES:
Progression-free survival (PFS) and overall survival (OS).RESULTS:
Lenvatinib was the first-line kinase-inhibitor in 96.4% of subjects. Median follow-up was 48 months. Median PFS and OS were 26 [95% confidence interval (CI) 19.06-32.93] and 70 months (95% CI 36-111.99), respectively. Pretreatmentsetting:
Eastern Cooperative Oncology Group (ECOG) performance status was independently related to PFS [P < .001; hazard ratio (HR) 18.82; 95% CI 3.65-97.08 score 0-1 as reference] and OS (P = .001; HR 6.20; 95% CI 2.11-18.20; score 0-1 as reference); radioactive iodine (RAI) avidity was independently related to PFS (P = .047; HR 3.74; 95% CI 1.01-13.76; avid disease as reference). Patients with good ECOG status (0-1) and RAI-avid disease obtained objective response in 100% of cases and achieved a median PFS of 45 months without any death upon a median follow-up of 81 months. Posttreatmentsetting:
the best radiological response independently predicted PFS (P = .001; HR 4.6; 95% CI 1.89-11.18; partial/complete response as reference) and OS (P = .013; HR 2.94; 95% CI 1.25-6.89; partial/complete response as reference).CONCLUSION:
RR-DTC with good performance status and RAI-avid disease obtains the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Neoplasias da Glândula Tireoide
/
Radioisótopos do Iodo
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália